-
The project funded through Luminesce Alliance Innovation in Paediatric Precision Medicine seed funding evaluated the efficacy of a new discovery to deliver radiation therapy to tumour cells. The new treatment modality, a protein will bind to dying/dead solid tumour cells and deliver therapeutic radiation to viable, potentially more resistant tumour cells adjacent to the dying /dead cells, and in combination with sensitising chemotherapy will generate a self-amplifying cascade of tumour cell kill.
The research results to date have been promising and have led to research funding and may lead to commercial opportunities. The results of the project have also been published in peer-reviewed journal publications (see links below) and presented at cancer research forums. Results from this project will be used to support further funding applications and commercial development. It is anticipated this research will provide the data required for human biodistribution and dosimetry studies, followed by a Phase 1 dose-escalation clinical trial. If successful, it could change the paradigm for treating cancers that are hard to reach and treat.
-
Professor Phil Hogg
(then) Deputy Director, Centenary Institute, Head, ACRF Centenary Cancer Research Centre, University of Sydney -
See Luminesce Alliance Publications – completed research – Tumour Cell Death Indicator (a self-amplifying theranostic for treatment of cancer)